HOXC8 and non-small cell lung carcinoma: We found that HOXC8 knockdown significantly enhanced cisplatin-induced repression on NSCLC viability (Fig. 7a), while HOXC8 ecto-expression attenuated the suppressive effects of cisplatin on both A549 and NCI-H460 cell viability (Fig. 7b).